-
Uncategorized4 weeks agoSTAT+: Why the WakeMed – Atrium Health hospital merger matters
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. Thanks for being here! So much to read, including a new...
-
Uncategorized4 weeks agoSTAT+: AstraZeneca picks up FDA approval for hypertension drug
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we’re bringing you a...
-
Uncategorized4 weeks agoU.S. bans entry for travelers from Ebola-affected countries
In response to a fast-moving Ebola outbreak, the Trump administration has imposed a U.S. entry ban on foreign travelers who have been in the Democratic Republic...
-
Uncategorized4 weeks agoFDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in...
-
Uncategorized4 weeks ago
Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
-
Uncategorized4 weeks ago
Is Revolution ‘the next oncology titan’? Truist analysts make the case
A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology...
-
Uncategorized4 weeks ago
Design Therapeutics’ Friedreich ataxia data; Vincentage’s obesity results from China
Design Therapeutics' Friedreich ataxia data; Vincentage's obesity results from China
-
Uncategorized4 weeks agoSTAT+: Supreme Court rejects challenge to Medicare drug price negotiation
WASHINGTON — The Supreme Court on Monday dealt a major blow to the brand drug industry’s legal campaign against the Medicare drug price negotiation program. The...
-
Uncategorized4 weeks ago
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
Right after reporting a major Phase 3 LAG-3 miss that has rattled analysts, Regeneron Pharmaceuticals revealed a back-loaded partnership with Parabilis Medicines aimed at adding a...
-
Uncategorized4 weeks agoSTAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online calls,...
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
